Mana Capital Acquisition (MAAQ) Competitors $4.28 -0.05 (-1.04%) As of 10/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MAAQ vs. CHRS, BIOA, GNLX, CRBP, FBRX, DERM, FATE, IPHA, TNXP, and FTLFShould you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Coherus Oncology (CHRS), BioAge Labs (BIOA), Genelux (GNLX), Corbus Pharmaceuticals (CRBP), Forte Biosciences (FBRX), Journey Medical (DERM), Fate Therapeutics (FATE), Innate Pharma (IPHA), Tonix Pharmaceuticals (TNXP), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Mana Capital Acquisition vs. Its Competitors Coherus Oncology BioAge Labs Genelux Corbus Pharmaceuticals Forte Biosciences Journey Medical Fate Therapeutics Innate Pharma Tonix Pharmaceuticals FitLife Brands Mana Capital Acquisition (NASDAQ:MAAQ) and Coherus Oncology (NASDAQ:CHRS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership. Is MAAQ or CHRS more profitable? Coherus Oncology has a net margin of 125.90% compared to Mana Capital Acquisition's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A Coherus Oncology 125.90%N/A -34.85% Do insiders & institutionals have more ownership in MAAQ or CHRS? 68.4% of Mana Capital Acquisition shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor MAAQ or CHRS? In the previous week, Coherus Oncology had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Coherus Oncology and 0 mentions for Mana Capital Acquisition. Coherus Oncology's average media sentiment score of 0.67 beat Mana Capital Acquisition's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Overall Sentiment Mana Capital Acquisition Neutral Coherus Oncology Positive Do analysts prefer MAAQ or CHRS? Coherus Oncology has a consensus price target of $4.51, indicating a potential upside of 152.09%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Mana Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Coherus Oncology 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has better valuation and earnings, MAAQ or CHRS? Coherus Oncology has higher revenue and earnings than Mana Capital Acquisition. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/ACoherus Oncology$266.96M0.78$28.51M$1.551.15 SummaryCoherus Oncology beats Mana Capital Acquisition on 9 of the 10 factors compared between the two stocks. Get Mana Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAAQ vs. The Competition Export to ExcelMetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$34.82M$34.82M$2.54B$10.68BDividend YieldN/AN/A2.49%4.83%P/E RatioN/AN/A21.9127.38Price / SalesN/AN/A113.01132.78Price / CashN/AN/A44.3430.35Price / BookN/AN/A35.226.68Net IncomeN/AN/A$6.87M$276.27M7 Day Performance3.25%3.25%0.82%0.95%1 Month Performance7.39%7.39%0.63%3.92%1 Year Performance1,931.77%1,931.77%126.44%36.33% Mana Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAAQMana Capital AcquisitionN/A$4.29-1.0%N/A+1,931.8%$34.82MN/A0.001CHRSCoherus Oncology4.1981 of 5 stars$1.67-8.2%$4.51+170.2%+86.9%$194.10M$266.96M1.08330BIOABioAge LabsN/A$5.35-1.8%N/AN/A$191.80MN/A0.00N/AHigh Trading VolumeGNLXGenelux0.8666 of 5 stars$5.07-10.6%$20.33+301.1%+108.0%$191.51M$10K-5.9010Gap UpCRBPCorbus Pharmaceuticals4.2245 of 5 stars$15.54-1.0%$45.43+192.3%+4.9%$190.44MN/A-3.2640News CoverageAnalyst ForecastGap UpHigh Trading VolumeFBRXForte Biosciences2.7975 of 5 stars$15.27+0.9%$68.00+345.3%+155.4%$189.85MN/A-0.945Analyst DowngradeShort Interest ↑DERMJourney Medical2.0188 of 5 stars$7.21-4.5%$12.17+68.7%+17.6%$189.70M$56.13M-18.9790FATEFate Therapeutics4.1224 of 5 stars$1.64+1.6%$3.30+101.8%-54.5%$188.56M$13.63M-1.13550Gap UpIPHAInnate Pharma2.1002 of 5 stars$2.03flat$6.50+220.2%+6.4%$187.13M$21.77M0.00220High Trading VolumeTNXPTonix Pharmaceuticals2.8077 of 5 stars$21.19-6.0%$70.00+230.3%+3.4%$185.75M$10.09M-0.5450Short Interest ↑Gap DownFTLFFitLife Brands3.5838 of 5 stars$19.70-3.5%$23.00+16.8%+13.2%$185M$64.47M23.4520 Related Companies and Tools Related Companies CHRS Alternatives BIOA Alternatives GNLX Alternatives CRBP Alternatives FBRX Alternatives DERM Alternatives FATE Alternatives IPHA Alternatives TNXP Alternatives FTLF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAAQ) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mana Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mana Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
